
News|Articles|February 1, 2008
FDA Pipeline Preview, February 2008
FDA-related information through February 2008 on Fluvoxamine extended-release capsules, dalbavancin, bazedoxifene, HPV vaccine (Cervarix), valrubicin, motexafin gadolinium, COL-003, CDX-110, sugammadex, mecaserim rinfabate, A-001, beclomethasone, clobazam, fludarabine tablets, JZP-8, and AST-120
Advertisement
Approvable designations
Complete response letter
Nonapprovable designations
Fast-track designations
Priority review
Orphan drug designations
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Neffy’s first year: $72.2m in sales, 10,000 schools and broadening payer access
2
Brukinsa/rituximab cuts progression risk 43% in mantle cell lymphoma
3
A conversation about vaccines and monoclonal antibodies with Marc Elia, Chairman of Invivyd’s Board of Directors
4
New study confirms benefits of GLP-1 drugs in patients with PAD
5
































